Flamel Technologies S.A. (NASDAQ:AVDL) CEO Michael S. Anderson acquired 4,000 shares of the business’s stock in a transaction on Tuesday, September 12th. The stock was acquired at an average price of $9.80 per share, with a total value of $39,200.00. The transaction was disclosed in a legal filing with the SEC, which is available at this link.
Shares of Flamel Technologies S.A. (AVDL) traded up 2.06% during trading on Friday, reaching $9.42. The company’s stock had a trading volume of 217,119 shares. The company has a market cap of $377.59 million, a PE ratio of 9.95 and a beta of 1.39. Flamel Technologies S.A. has a 52-week low of $8.14 and a 52-week high of $14.15. The firm’s 50-day moving average is $9.03 and its 200 day moving average is $9.82.
Flamel Technologies (NASDAQ:AVDL) last issued its earnings results on Tuesday, August 8th. The company reported $0.19 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.05 by $0.14. The firm had revenue of $46.30 million for the quarter, compared to the consensus estimate of $45.17 million. Flamel Technologies had a return on equity of 29.84% and a net margin of 21.13%. The company’s quarterly revenue was up 19.0% on a year-over-year basis. On average, equities research analysts predict that Flamel Technologies S.A. will post $1.16 EPS for the current fiscal year.
WARNING: “Flamel Technologies S.A. (AVDL) CEO Purchases $39,200.00 in Stock” was reported by TrueBlueTribune and is the property of of TrueBlueTribune. If you are accessing this piece on another site, it was stolen and republished in violation of United States and international copyright law. The legal version of this piece can be accessed at https://www.truebluetribune.com/2017/09/17/flamel-technologies-s-a-avdl-ceo-purchases-39200-00-in-stock.html.
AVDL has been the subject of several research analyst reports. Zacks Investment Research downgraded Flamel Technologies from a “hold” rating to a “sell” rating in a research report on Monday, August 7th. Langenberg & Company reiterated a “buy” rating and issued a $30.00 price objective (up previously from $27.00) on shares of Flamel Technologies in a research report on Thursday, September 7th. Ladenburg Thalmann Financial Services lifted their price objective on Flamel Technologies from $27.00 to $30.00 in a research report on Thursday, September 7th. Finally, Roth Capital set a $15.00 price objective on Flamel Technologies and gave the company a “buy” rating in a research report on Wednesday, August 9th. One equities research analyst has rated the stock with a sell rating and four have given a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $19.83.
Several hedge funds have recently modified their holdings of AVDL. PNC Financial Services Group Inc. boosted its holdings in shares of Flamel Technologies by 2,484.0% in the 2nd quarter. PNC Financial Services Group Inc. now owns 10,956 shares of the company’s stock valued at $121,000 after purchasing an additional 10,532 shares in the last quarter. US Bancorp DE acquired a new stake in shares of Flamel Technologies in the 1st quarter valued at $121,000. Sei Investments Co. boosted its holdings in shares of Flamel Technologies by 29.5% in the 2nd quarter. Sei Investments Co. now owns 12,726 shares of the company’s stock valued at $140,000 after purchasing an additional 2,900 shares in the last quarter. Arrowstreet Capital Limited Partnership acquired a new stake in shares of Flamel Technologies in the 2nd quarter valued at $181,000. Finally, State of Tennessee Treasury Department acquired a new stake in shares of Flamel Technologies in the 2nd quarter valued at $194,000. 69.09% of the stock is currently owned by hedge funds and other institutional investors.
About Flamel Technologies
Flamel Technologies SA is a specialty pharmaceutical company. The Company is engaged in the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its polymer based technology. The Company has a balanced business model consisting of an Unapproved Marketed Drugs (UMDs) business with over two approved products in the United States, Bloxiverz (neostigmine methylsulfate injection) and Vazculep (phenylephrine hydrochloride injection) that are marketed; a branded pediatric business, and a branded business, focusing on the development of products utilizing Flamel’s drug delivery platforms.
Receive News & Ratings for Flamel Technologies S.A. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flamel Technologies S.A. and related companies with MarketBeat.com's FREE daily email newsletter.